Karison (Clobetasol Propionate)

Clobetasol propionate penetrates the skin and binds to intracellular glucocorticoid receptors. The drug‑receptor complex moves into the nucleus, where it alters gene transcription, suppresses pro‑inflammatory cytokines, inhibits phospholipase A2, and reduces leukocyte migration. These actions produce strong anti‑inflammatory, immunosuppressive and vasoconstrictive effects on the skin.

The appropriate amount of Karison is determined by the prescribing healthcare professional based on the specific condition, severity, patient age, and treatment duration. Dosage instructions are individualized; patients should follow the prescriber’s guidance and not alter the amount or frequency without medical advice.

Safety data for clobetasol propionate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their physician before use.

To order Karison, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Karison (clobetasol propionate) is a class‑I, high‑potency corticosteroid, offering stronger anti‑inflammatory activity than mid‑potency agents such as betamethasone dipropionate. It is typically reserved for severe or resistant dermatoses and used for short periods to minimize adverse effects. Lower‑potency steroids may be preferred for mild disease or sensitive areas.

Karison should be stored at room temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme heat. Keep the packaging tightly closed when not in use and keep it out of reach of children.

Clean and gently dry the affected skin area before use. Apply a thin layer of Karison to the lesion once or twice daily, as directed by the prescriber. Avoid contact with eyes, mucous membranes, and broken skin unless specifically instructed. Wash hands after application.

Serious adverse effects include skin atrophy (thinning), telangiectasia, secondary bacterial or fungal infections, and systemic adrenal suppression with extensive use. Patients should monitor for unusual skin thinning, persistent bruising, or signs of hormonal imbalance and report these promptly to their healthcare provider.

Karison is contraindicated in patients with known hypersensitivity to clobetasol propionate or any excipients, in untreated viral, bacterial or fungal skin infections, and in individuals with skin conditions caused by organisms that may worsen with steroid use (e.g., acne rosacea). Caution is also advised for children under 12 years unless specifically prescribed.